+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice

Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice

Journal of Neural Transmission 110(12): 1375-1391

The aim of this study was to evaluate the effect of MPTP (2 x 45 mg/kg s.c., 20 h apart) on striatal neuropeptide Y-like immunoreactivity (NPY-LI) in C57BL/6 mice. NPY-LI markedly increased 2 weeks after MPTP but it remained unchanged after 24 h, 1 or 6 weeks. The increase in NPY-LI was accompanied by depletion of dopamine (-80%), DOPAC (-70%), 3-MT (-44%) and HVA (-52%). L-Deprenyl completely prevented the MPTP-induced NPY-LI increase, neurodegeneration of the striatal dopamine system and motor dysfunction. Clonidine attenuated the neurotoxin effect on NPY-LI and dopaminergic neurons. L-dopa/carbidopa protected NPY neurons against MPTP but slightly enhanced MPTP-induced decrease in the levels of dopamine and its metabolites. The relationship between changes in NPY-LI and dopamine and serotonin metabolism determined by HPLC was discussed. The results further extend the range of MPTP-elicited modifications in striatum and demonstrate that drugs with antiparkinsonian activity can protect NPY neurons against MPTP toxicity.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 012200488

Download citation: RISBibTeXText

PMID: 14666410

DOI: 10.1007/s00702-003-0047-1

Related references

Estrogen Increases Striatal GDNF Immunoreactivity with no Effect on Striatal FGF-2 Immunoreactivity of MPTP-Treated Mice. Journal of the Medical Association of Thailand 98(Suppl. 9): S16-S22, 2015

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115(4): 1047-1058, 16 December, 2002

Novel sites of action for deprenyl in MPTP-parkinsonism: metabolite-mediated protection against striatal neurotoxicity and suppression of MPTP-induced increase of dopamine turnover in C57BL mice. Progress in Brain Research 106: 155-171, 1995

The effect of estrogen upon L-DOPA evoked striatal dopamine release in vitro in MPTP-treated female mice. Society for Neuroscience Abstracts 18(1-2): 1578, 1992

L-deprenyl in prevention of MPTP induced depletion of striatal enkephalins in mice. Chinese Medical Journal 101(4): 292-294, 1988

Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice. Journal of Neuroscience Research 23(3): 326-329, 1989

Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats. Neurotoxicity Research 5(8): 569-577, 2004

Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration. Neurobiology of Disease 20(2): 347-359, 2005

Significant up-regulation of nestin protein in the neostriatum of MPTP-treated mice. Are the striatal astrocytes regionally activated after systemic MPTP administration?. Brain Research 925(1): 9-17, 18 January, 2002

Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease. Japanese Journal of Pharmacology 55(1): 93, 1991

Changes in striatal preproenkephalin A and preprotachykinin mRNA expression The effect of L-dopa, bromocriptine, and ropinirole in MPTP-treated marmosets. Neurology 50(4 Suppl. 4): A135, 1998

Differential effects of ropinirole, bromocriptine and L-DOPA on striatal preprodynorphin mRNA expression in the MPTP-treated marmoset. British Journal of Pharmacology 128(PROC Suppl. ): 282P, 1999